Ann: MDR Quarterly Report & Appendix 4C, page-6

  1. 4,217 Posts.
    lightbulb Created with Sketch. 238
    Demand for vaccination delivery via retail pharmacies is expected to grow - this will accelerate opportunities to market MedAdvisor/Adheris Health services, especially with multiple vaccine manufacturers.

    The ASX have been cracking down on COVID announcements, especially with the multiple listed hand sanitiser companies, but the above would be referring to coronavirus vaccines. This is likely to be a big program for MedAdvisor.

    https://www.biopharmadive.com/news/coronavirus-vaccine-pipeline-types/579122/
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
8.0¢
Change
0.001(1.27%)
Mkt cap ! $49.98M
Open High Low Value Volume
7.9¢ 8.0¢ 7.9¢ $45.78K 576.6K

Buyers (Bids)

No. Vol. Price($)
1 120000 7.7¢
 

Sellers (Offers)

Price($) Vol. No.
8.0¢ 60937 1
View Market Depth
Last trade - 16.10pm 17/06/2025 (20 minute delay) ?
MDR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.